Homepage6160 • HKG
add
BeOne Medicines AG
Vorige slotkoers
$Â 190,00
Dag-range
$Â 181,60 - $Â 192,30
Jaar-range
$Â 103,10 - $Â 213,00
Beurswaarde
295,31Â mld. HKD
Gem. volume
5,77Â mln.
Koers/winst
-
Dividendrendement
-
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 1,32Â mld. | 41,56% |
Bedrijfskosten | 537,91Â mln. | 21,23% |
Netto inkomsten | 94,32Â mln. | 178,34% |
Netto winstmarge | 7,17 | 155,32% |
Winst per aandeel | 0,43 | 137,48% |
EBITDA | 117,75Â mln. | 241,18% |
Effectief belastingtarief | 5,25% | — |
Balans
Totale activa
Totale passiva
| (USD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 2,76Â mld. | 6,30% |
Totale activa | 6,30Â mld. | 10,26% |
Totale passiva | 2,53Â mld. | 7,76% |
Totaal aandelenvermogen | 3,77 mld. | — |
Uitstaande aandelen | 110,03 mln. | — |
Koers-boekwaardeverhouding | 5,54 | — |
Rendement op activa | 3,62% | — |
Rendement op kapitaal | 4,73% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 94,32Â mln. | 178,34% |
Operationele kasstroom | 263,60Â mln. | 375,76% |
Kasstroom uit beleggingen | -66,60Â mln. | 40,01% |
Kasstroom uit financiering | 35,02Â mln. | 52,17% |
Nettomutatie in liquide middelen | 255,50Â mln. | 234,82% |
Vrije kasstroom | 180,43Â mln. | 247,61% |
Over
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Opgericht
28 okt 2010
Website
Werknemers
11.000
